A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I
A phase 3 trial of Intismeran autogene in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Overview
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) is a phase 3 interventional study registered as NCT07513376 by Merck Sharp & Dohme LLC, with 876 participants planned, started 2026-05-04 and due to reach its primary completion in 2034-08-22. Interventions recorded: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (
Shares Intismeran autogene, Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Shares Intismeran autogene, Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)
Shares Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Shares Intismeran autogene, Merck & Co. (MSD).
- TrialA Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Shares Intismeran autogene, Merck & Co. (MSD).
- TrialA Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).
Shares Intismeran autogene, Merck & Co. (MSD).
- TrialSacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With P
Shares Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrol
Shares Merck & Co. (MSD), Small-cell lung cancer, Non-small-cell lung cancer.